Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT06986369
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 140 participants
- Sponsor
- Registry
-
NCT06986369
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06986369. Randomized; double masking; primary purpose treatment. Start 2021-05-04 (actual); primary completion 2023-08-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases
- Condition
- Atherosclerosis, Coronary
- Intervention (Drug)
- Rivaroxaban 2.5 MG Oral Tablet [Xarelto]
- Lead sponsor
- The University of Hong Kong
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct06986369- Content hash
078d0a1bd51194abbac8ad60ff81f698d9f54ae9f33e45719535e1866bbc3b90